| Chronic Lymphocytic Leukemia |
1 |
1 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.9 |
| Food and Drug Administration (FDA) |
0 |
0.98 |
| Lymphoma |
0 |
0.57 |
| Follicular Lymphoma |
0 |
0.5 |
| Patient Safety |
0 |
0.99 |
| Adverse Effects |
0 |
0.21 |
| Refractory |
0 |
0.21 |
| Leukemia |
0 |
0.14 |
| Biologic Therapy |
0 |
0.12 |
| Aminotransferase |
0 |
0.1 |
| Hepatocellular Carcinoma |
0 |
0.09 |
| Blood |
0 |
0.07 |
| Cancer |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Diarrhea |
0 |
0.07 |
| Drug and Treatment Safety |
0 |
0.07 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Liver |
0 |
0.07 |
| Lung |
0 |
0.07 |
| Monoclonal Antibody |
0 |
0.07 |